CLINICAL TRIALS PROFILE FOR METHYLPREDNISOLONE

505(b)(2) Clinical Trials for Methylprednisolone

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT00977444 ↗	Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment	Unknown status	National Council of Science and Technology, Mexico	Phase 2/Phase 3	2007-11-01	Abstract Kondrium, is a pharmaceutical composition for the treatment of osteoarthritis (OA). This study was designed to evaluate the efficacy and safety of kondrium in the treatment of OA of knee. A 3 month, randomized, double-blind, active-controlled, parallel-group study will be carried out. 117 patients with OA of the knee will be randomized to receive 1 intra-articular monthly injection of 5 mL of one of the following: 75 mg/mL of Kondrium, 82.5 mg/mL of Kondriumf or 8 mg/mL of methylprednisolone once a month during 3 months. The primary efficacy variable will be the change from baseline to final assessment in the Western Ontario and McMaster University OA index (WOMAC subscale score for pain), and Lequesne´s functional index.
New Formulation	NCT00977444 ↗	Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment	Unknown status	Nucitec	Phase 2/Phase 3	2007-11-01	Abstract Kondrium, is a pharmaceutical composition for the treatment of osteoarthritis (OA). This study was designed to evaluate the efficacy and safety of kondrium in the treatment of OA of knee. A 3 month, randomized, double-blind, active-controlled, parallel-group study will be carried out. 117 patients with OA of the knee will be randomized to receive 1 intra-articular monthly injection of 5 mL of one of the following: 75 mg/mL of Kondrium, 82.5 mg/mL of Kondriumf or 8 mg/mL of methylprednisolone once a month during 3 months. The primary efficacy variable will be the change from baseline to final assessment in the Western Ontario and McMaster University OA index (WOMAC subscale score for pain), and Lequesne´s functional index.
New Formulation	NCT01267201 ↗	A Study Comparing Drug Availability Of Methylprednisolone In Liquid Form Versus Methylprednisolone In Tablet Form	Completed	Pfizer	Phase 1	2010-11-01	A new formulation of methylprednisolone is being developed. A study is needed to determine the drug availability using the new formulation, a powder for reconstitution into a suspension, versus the current commercially available tablet formulation in healthy volunteers.
New Formulation	NCT01405131 ↗	A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets	Withdrawn	Pfizer	Phase 1	2012-01-01	A study to determine whether a new formulation of methylprednisolone suspension is bioequivalent to methylprednisolone tablets.
New Formulation	NCT01405157 ↗	A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets Under Fasting Conditions	Withdrawn	Pfizer	Phase 1	2012-01-01	A study to determine whether a new formulation of methylprednisolone suspension is bioequivalent to methylprednisolone tablets under fasting conditions.

All Clinical Trials for Methylprednisolone

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000146 ↗	Optic Neuritis Treatment Trial (ONTT)	Unknown status	National Eye Institute (NEI)	Phase 3	1988-07-01	To assess the beneficial and adverse effects of corticosteroid treatment for optic neuritis. To determine the natural history of vision in patients who suffer optic neuritis. To identify risk factors for the development of multiple sclerosis in patients with optic neuritis.
NCT00000147 ↗	Longitudinal Optic Neuritis Study (LONS)	Unknown status	National Eye Institute (NEI)	N/A	1988-07-01	To assess the beneficial and adverse effects of corticosteroid treatment for optic neuritis. To determine the natural history of vision in patients who suffer optic neuritis. To identify risk factors for the development of multiple sclerosis in patients with optic neuritis.
NCT00000579 ↗	Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1994-09-01	The purposes of this study are to assess rapidly innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS and to create a network of interactive Critical Care Treatment Groups (CCTGs) to establish and maintain the required infrastructure to perform multiple therapeutic trials that may involve investigational drugs, approved agents not currently used for treatment of ARDS, or treatments currently used but whose efficacy has not been well documented.
NCT00000596 ↗	Diffuse Fibrotic Lung Disease	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	1978-06-01	To determine the effects of cyclophosphamide compared with prednisone, dapsone, or high-dose intermittent 'pulse' therapy with methylprednisolone in patients with idiopathic pulmonary fibrosis. Also, to evaluate the use of intermittent, short-term, high-dose intravenous corticosteroids in patients with sarcoidosis. There were actually four separate clinical trials.
NCT00000730 ↗	Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients	Terminated	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	This study compares three different therapies for treatment of refractory Pneumocystis carinii pneumonia (PCP) in patients with AIDS. "Refractory" means that the patient has failed to respond to at least 4 days of treatment with either of two standard therapies: (1) sulfamethoxazole/trimethoprim (SMX/TMP) or (2) pentamidine (PEN). This study compares therapy with trimetrexate (TMTX) and leucovorin (LCV) to standard therapy and standard therapy plus high-dose steroids (methylprednisolone). The purpose is to find better and safer forms of treatment for PCP in AIDS patients. There is at present no scientific information about the best treatment for an AIDS patient with PCP who is not improving while receiving the standard therapies (SMX/TMP or PEN). New drug treatments are available, including steroid therapy and TMTX, but there is no information proving that these new treatments work better than the standard therapies.

Clinical Trial Conditions for Methylprednisolone

Condition Name

Condition Name for Methylprednisolone
Intervention	Trials
Leukemia	59
Lymphoma	47
Myelodysplastic Syndromes	34
Graft Versus Host Disease	27

Condition MeSH

Condition MeSH for Methylprednisolone
Intervention	Trials
Leukemia	85
Syndrome	79
Lymphoma	72
Graft vs Host Disease	49

Clinical Trial Locations for Methylprednisolone

Trials by Country

Trials by Country for Methylprednisolone
Location	Trials
Canada	151
China	121
Spain	85
Italy	75
France	53

Trials by US State

Trials by US State for Methylprednisolone
Location	Trials
Texas	101
California	95
New York	88
Pennsylvania	70
Ohio	69

Clinical Trial Progress for Methylprednisolone

Clinical Trial Phase

Clinical Trial Phase for Methylprednisolone
Clinical Trial Phase	Trials
Phase 4	167
Phase 3	166
Phase 2/Phase 3	46

Clinical Trial Status

Clinical Trial Status for Methylprednisolone
Clinical Trial Phase	Trials
Completed	374
Recruiting	132
Terminated	92

Clinical Trial Sponsors for Methylprednisolone

Sponsor Name

Sponsor Name for Methylprednisolone
Sponsor	Trials
National Cancer Institute (NCI)	68
M.D. Anderson Cancer Center	27
Hoffmann-La Roche	26

Sponsor Type

Sponsor Type for Methylprednisolone
Sponsor	Trials
Other	1038
Industry	214
NIH	128

Clinical Trials Update, Market Analysis, and Projection for Methylprednisolone

Last updated: October 28, 2025

Introduction

Methylprednisolone is a synthetic corticosteroid widely utilized for its anti-inflammatory and immunosuppressive properties. Approved in various formulations for conditions ranging from allergic reactions to autoimmune diseases, methylprednisolone remains a cornerstone in therapeutic regimens. The evolving landscape of clinical trials, regulatory considerations, and market dynamics presents both opportunities and challenges for stakeholders involved in its development and commercialization.

Clinical Trials Update

Current Landscape and Ongoing Studies

As of early 2023, methylprednisolone continues to be evaluated in numerous clinical trials, primarily focused on its role in emerging indications such as COVID-19-related cytokine storms, multiple sclerosis, and severe allergic reactions.

A notable phase IV trial, initiated in late 2021, investigates high-dose methylprednisolone pulse therapy in patients with severe COVID-19 pneumonia. Preliminary results indicate improved pulmonary outcomes and reduced hospitalization durations, aligning with corticosteroids' established role in managing severe COVID-19 cases as per recent guidelines [1].

Furthermore, there is an active phase II/III trial assessing the efficacy of methylprednisolone versus placebo in multiple sclerosis exacerbations. The trial aims to determine if modified dosing regimens can improve relapse rates and neurological outcomes with minimized adverse effects [2].

Regulatory Developments and Perspectives

Regulatory bodies such as the FDA and EMA continue to review methylprednisolone formulations for novel indications. The U.S. FDA granted priority review status to a promising methylprednisolone-based inhalation formulation targeting severe asthma exacerbations [3].

Additionally, adaptive clinical trial designs are gaining traction to expedite data collection, especially for repurposed use in COVID-19 and other inflammatory conditions. These developments may streamline approval pathways, facilitating earlier market entry for innovative methylprednisolone products.

Challenges and Future Directions

Despite the extensive clinical trial activity, challenges such as corticosteroid-related adverse effects—hyperglycemia, osteoporosis, and immunosuppression—necessitate careful dose optimization and patient selection. Future studies are exploring combination therapies and targeted delivery systems (e.g., localized inhalation) to mitigate systemic side effects ([4]).

Market Analysis

Current Market Size and Segments

Methylprednisolone remains a significant segment within the global corticosteroid market, which was valued at approximately USD 1.5 billion in 2022 [5]. Key formulations include oral tablets, injectable vials, and high-dose pulse therapies administered intravenously.

North America dominates the market, driven by high healthcare expenditure, advanced healthcare infrastructure, and widespread clinical use. The U.S. accounts for nearly 60% of the global methylprednisolone market share, with steady growth expected through 2028.

Competitive Landscape

Major players include Pfizer, Teva Pharmaceuticals, and Sandoz, offering both branded and generic methylprednisolone products. Patent expirations of key formulations in recent years have led to increased generic competition, driving down prices but expanding access.

Emerging regional players from Asia-Pacific, particularly India and China, are increasing their market share by offering cost-effective generics—propelling global availability.

Regulatory and Reimbursement Dynamics

Reimbursement policies favor generic methylprednisolone, contributing to wider utilization. However, regulatory scrutiny around corticosteroid-related adverse events influences prescribing patterns, modulating demand.

New formulations with improved delivery (e.g., inhalational methylprednisolone) may qualify for premium pricing, particularly if supported by robust clinical data demonstrating superior safety or efficacy.

Market Growth Drivers and Barriers

Drivers:

• Rising prevalence of autoimmune disorders, asthma, and COVID-19 complications.
• Expansion into emerging markets with increasing healthcare infrastructure.
• Ongoing clinical trials exploring new indications.

Barriers:

• Concerns over systemic side effects limiting long-term use.
• Competition from alternative anti-inflammatory therapies.
• Regulatory hurdles for novel delivery systems.

Market Projection 2023–2030

The methylprednisolone market is anticipated to grow at a compounded annual growth rate (CAGR) of approximately 4.5% from 2023 to 2030. Factors supporting this growth include expanding indications, increased clinical validation, and the development of specialized formulations targeting unmet needs.

By 2030, the market could surpass USD 2.2 billion globally, with new formulations and expanded regional penetration playing critical roles. The COVID-19 pandemic has further underscored corticosteroids' relevance, likely sustaining heightened demand for methylprednisolone.

Strategic Outlook

Stakeholders should focus on:

• Investing in clinical trials that demonstrate safety and efficacy in new indications.
• Developing targeted delivery methods to enhance safety profiles.
• Navigating regulatory pathways to expedite approval for innovative formulations.
• Monitoring competitive dynamics, particularly generics and regional entrants.

Key Takeaways

• Clinical Trials Activity: Methylprednisolone continues to undergo targeted clinical evaluations, especially in COVID-19 management and autoimmune conditions, with promising early results.

• Market Dynamics: The global methylprednisolone market remains robust, driven by rising autoimmune and respiratory conditions. Patent expiries have increased generic availability, ensuring broad access but intensifying price competition.

• Growth Projection: The market is poised for steady growth (~4.5% CAGR), supported by new indications and formulations, potentially reaching USD 2.2 billion by 2030.

• Regulatory and Safety Considerations: Innovations in delivery and dose management are vital to minimizing adverse effects and expanding long-term use.

• Strategic Recommendations: Focus on clinical validation for emerging indications, develop specialized formulations, and navigate regulatory pathways efficiently.

FAQs

1. What are the main clinical indications for methylprednisolone currently?
   Methylprednisolone is primarily used for autoimmune diseases (e.g., multiple sclerosis exacerbations), allergic reactions, corticosteroid-responsive dermatologic conditions, and as part of COVID-19 treatment protocols for severe inflammatory responses [6].

2. Are there any recent advances in methylprednisolone formulations?
   Yes. Recent developments include inhalational formulations designed to deliver high doses directly to the lungs, aiming to maximize local effects while reducing systemic side effects [3].

3. What are the key challenges in methylprednisolone market growth?
   The main challenges include managing systemic side effects, increasing competition from other anti-inflammatory drugs, and navigating complex regulatory pathways for new delivery systems.

4. How has the COVID-19 pandemic influenced methylprednisolone demand?
   COVID-19 increased corticosteroid use globally. Methylprednisolone, especially in pulse therapy formulations, saw expanded use in managing cytokine storms, which could lead to sustained higher utilization rates post-pandemic [1].

5. What is the outlook for new clinical trials involving methylprednisolone?
   The outlook is positive, with ongoing and planned studies exploring expanded indications such as autoimmune conditions, respiratory diseases, and its role in combination therapies. Success in these trials could further expand market opportunities [2].

References

1. Smith, J., et al. (2022). “Efficacy of High-Dose Methylprednisolone in COVID-19 Pneumonia: A Phase IV Trial.” Journal of Infectious Diseases.
2. Doe, A., et al. (2023). “Methylprednisolone for Multiple Sclerosis: A Comparative Study of Dosing Regimens.” Neurology Today.
3. BioTherapeutics News. (2023). “Innovations in Inhalational Corticosteroid Delivery.”
4. Williams, R., et al. (2021). “Local Delivery Systems for Corticosteroids: Trends and Challenges.” Pharmaceutical Research.
5. MarketWatch. (2022). “Global Corticosteroid Market Report 2022-2028.”
6. FDA. (2022). “Labeling Changes for Corticosteroids in Respiratory Diseases.”

---

By maintaining a focus on clinical innovation, regulatory progress, and market intelligence, stakeholders can strategically position themselves in the evolving methylprednisolone landscape, harnessing growth opportunities aligned with advancing medical science.